---
figid: PMC6518944__IMR-288-214-g004
figtitle: Aberrant BCR signaling in GC‐derived B‐cell lymphomas
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC6518944
filename: IMR-288-214-g004.jpg
figlink: /pmc/articles/PMC6518944/figure/imr12755-fig-0004/
number: F4
caption: 'Aberrant BCR signaling in GC‐derived B‐cell lymphomas. BCR signaling is
  essential for mature B‐cell survival. Most GC‐derived lymphomas hijack BCR and/or
  PI3K signaling, including: BL, FL, the ABC‐DLBCL subtypes C5 and MCD, and the GCB‐DLBCL
  subtypes C3 and EZB. Depicted are the most frequent mutations that promote aberrant
  BCR/PI3K signaling activation in these lymphomas. Alterations that affect indirect
  modulators of the PI3K pathway such as PTEN and MIR17HG are more reminiscent of
  antigen‐independent “tonic” BCR signaling than antigen‐dependent “chronic‐active”
  BCR signaling. *MYD88 is mutated in ABC‐DLBCL but not in FL. Concurrent mutations
  of CD79A/B and MYD88 are most common in C5 and MCD lymphomas and less so in other
  lymphomas. BL, Burkitt lymphoma; FL, follicular lymphoma; DLBCL, diffuse large B‐cell
  lymphoma'
papertitle: 'Germinal center‐derived lymphomas: The darkest side of humoral immunity.'
reftext: Coraline Mlynarczyk, et al. Immunol Rev. 2019 Mar;288(1):214-239.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9678978
figid_alias: PMC6518944__F4
figtype: Figure
redirect_from: /figures/PMC6518944__F4
ndex: bedb6cf3-decb-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6518944__IMR-288-214-g004.html
  '@type': Dataset
  description: 'Aberrant BCR signaling in GC‐derived B‐cell lymphomas. BCR signaling
    is essential for mature B‐cell survival. Most GC‐derived lymphomas hijack BCR
    and/or PI3K signaling, including: BL, FL, the ABC‐DLBCL subtypes C5 and MCD, and
    the GCB‐DLBCL subtypes C3 and EZB. Depicted are the most frequent mutations that
    promote aberrant BCR/PI3K signaling activation in these lymphomas. Alterations
    that affect indirect modulators of the PI3K pathway such as PTEN and MIR17HG are
    more reminiscent of antigen‐independent “tonic” BCR signaling than antigen‐dependent
    “chronic‐active” BCR signaling. *MYD88 is mutated in ABC‐DLBCL but not in FL.
    Concurrent mutations of CD79A/B and MYD88 are most common in C5 and MCD lymphomas
    and less so in other lymphomas. BL, Burkitt lymphoma; FL, follicular lymphoma;
    DLBCL, diffuse large B‐cell lymphoma'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - C5
  - MUC1
  - MLYCD
  - C3
  - HVCN1
  - BCR
  - RN7SL263P
  - CD19
  - SYK
  - BLNK
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - BTK
  - PLCG1
  - PLCG2
  - IGH
  - IGHV3OR16-7
  - IGHV3-69-1
  - PTPN6
  - NR0B2
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - PTEN
  - TCF3
  - TCF7L1
  - TLR9
  - MIR17HG
  - MIR18A
  - MIR19A
  - MIR19B1
  - MIR20A
  - MIR92A1
  - PDK1
  - PDPK1
  - ID3
  - CARD11
  - BCL10
  - MYD88
  - MALT1
  - IRAK1
  - IRAK4
  - AKT1
  - AKT2
  - AKT3
  - TRAF6
  - TNFAIP3
  - NFKBIE
  - NFKBIA
  - MTOR
  - IKBKG
  - IKBKB
  - CHUK
  - CD79A
  - CD79B
  - MCD
---
